Water-soluble saffron pigments, taken as an isolated compound. Best supported: lower inflammation markers and modestly better blood sugar control. Smaller signals for mood, blood pressure and eye health. Everything beyond rests on single studies, seller-run trials, or animals. Blood pressure falls, a kidney marker rises, clotting time shortens. Whole saffron extract outperforms the purified pigment on metabolic measures. (Full Review)
| Marker | Target | Why |
|---|---|---|
| High-sensitivity C-reactive protein | < 1.0 mg/L | Primary target; the marker crocins move most reliably |
| Serum creatinine | 0.6–1.0 mg/dL (women), 0.7–1.2 mg/dL (men) | Detects the creatinine rise seen in pooled crocin trials |
| Estimated glomerular filtration rate | > 90 mL/min/1.73 m² | Puts any creatinine shift in context of actual kidney capacity |
| Fasting glucose | 75–86 mg/dL | Tracks the glycemic benefit where metabolic gain is the goal |
| HbA1c | 4.8–5.2% | Three-month average blood sugar; the endpoint that moved in pooled crocin trials |
| Systolic blood pressure | 105–120 mmHg | Detects additive lowering with antihypertensive medication |
| Complete blood count with differential | White cells 4.0–10.0 × 10⁹/L | Covers the leukopenia signal seen alongside chemotherapy |
| Partial thromboplastin time | 25–35 seconds | Clotting-speed test; shortened in the dedicated crocin safety trial |
| Central retinal thickness | No established target; track change from own baseline | The endpoint that improved in diabetic macular swelling |
Cadence: Baseline before starting; blood pressure weekly for the first four weeks; full panel at 12 weeks; thereafter every 6–12 months while use continues.